Clinical trial
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
NCT04877457
Study timeline
Study start (actual)2022-02-15Date precision: day
Registry last updated2024-10-09
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Radiologically Isolated Syndromeunresolved
Multiple Sclerosisunresolved
Interventions
OcrelizumabDRUG · verified · RxNorm: ocrelizumab
PlaceboOTHER
Sponsors & collaborators
Yale Universitylead sponsor
Genentech, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04877457 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.